Home | Neuromuscular | Duchenne muscular dystrophy (DMD) | Congress activities | American Academy of Neurology Annual Meeting (AAN) | AAN 2022 poster: Associations between deflazacort versus prednisone/prednisolone and markers of disease progression in clinically important subgroups of patients with Duchenne muscular dystrophy

AAN 2022 poster: Associations between deflazacort versus prednisone/prednisolone and markers of disease progression in clinically important subgroups of patients with Duchenne muscular dystrophy

Presented at the 2022 AAN Annual Meeting in Seattle, USA, this poster shows results from a study investigating disease progression following treatment with different corticosteroids for Duchenne muscular dystrophy (DMD)

  • Learn about the study design and baseline characteristics of patients with DMD from 4 clinical trials, who were investigated in this research
  • Read more on the primary and secondary endpoints used to assess the effect of treatment with different corticosteroids
  • Find out about the clinical effect of different corticosteroids in patients with DMD, stratified by age, length of corticosteroid use, and stage of disease progression

Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.

For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at usmedinfo@ptcbio.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

Registration
  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

    *
    *
  • PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

MED-ALL-DMD-2200110 | May 2022
Sign in or register to access exclusive content on this site 
  REGISTER

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.